KURA Kacepetan wutah bathi saben saham ing taun lumaku Kura

Lambang korporat lan logo Kura Oncology, Inc. (KURA)

Stable laboratory utilization and facility modernization support the year-over-year shift in earnings per share for Kura Oncology, Inc. (KURA). -1.60 shapes the current metric. The business foundation relies on ESG standards and clinical ethics, as well as the diversification of developments to combat hematological and solid tumors. Analysis of this chart allows for the identification of trend reversal points and an assessment of drawdown risks.

KURA - Wutah bathi saben saham ing taun lumaku Kura Oncology ing rentang 04.07.2022 - 18.11.2026

Rincian analitis lan laporan data perusahaan Kura Oncology (KURA)

- nilai saham lan prakiraan konsensus rega:
Pambiji fundamental:Kura Oncology, Inc.
Produk asil prodhuksi kuraoncology.com

This indicator captures the annual percentage change in earnings per share, allowing for an assessment of business capitalization efficiency relative to the previous period. By analyzing the YoY net income per share trend, an investor can see the impact of bioanalysis robotization costs and precision inhibitor testing on the final profitability of Kura Oncology, Inc. (KURA) during the acceleration of preclinical research.